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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to a 
combination of pomegranate pomace extract and greater galangal rhizome 
powder and an increase in the number of motile spermatozoa in semen 
pursuant to Article 13(5) of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2,3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from Nerthus ApS, submitted for authorisation of a health claim pursuant to 
Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Denmark, the EFSA Panel on 
Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation 
of a health claim related to a combination of pomegranate pomace extract (standardised by its content of 
punicalagins) and greater galangal rhizome powder (standardised by its content of acetoxychavicol acetate) and 
an increase in the number of motile spermatozoa in semen. The Panel considers that the food is sufficiently 
characterised. An increase in the number of motile spermatozoa in semen is a beneficial physiological effect. In 
weighing the evidence, the Panel took into account that one human study showed an increase in the number of 
motile spermatozoa in semen when the combination of pomegranate pomace extract and greater galangal rhizome 
powder was consumed for three months, that no other human studies in which these results have been replicated 
were provided, and that no evidence was provided for a mechanism by which the food could exert the claimed 
effect. The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the combination of pomegranate pomace extract (standardised by its content of punicalagins) and 
greater galangal rhizome powder (standardised by its content of acetoxychavicol acetate) and an increase in the 
number of motile spermatozoa in semen. 
© European Food Safety Authority, 2015 
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SUMMARY 
Following an application from Nerthus ApS, submitted for authorisation of a health claim pursuant to 
Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Denmark, the EFSA 
Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the 
scientific substantiation of a health claim related to a combination of pomegranate pomace extract and 
greater galangal rhizome powder and an increase in the number of motile spermatozoa in semen. 
The scope of the application was proposed to fall under a health claim based on newly developed 
scientific evidence. The application included a request for the protection of proprietary data. 
The food that is the subject of the health claim is a combination of pomegranate (Punica granatum L.) 
pomace extract and greater galangal (Alpinia galanga (L.) Willd.) rhizome powder. The Panel 
considers that the food, a combination of pomegranate pomace extract (standardised by its content of 
punicalagins) and greater galangal rhizome powder (standardised by its content of acetoxychavicol 
acetate), is sufficiently characterised. 
The claimed effect is “increases the number of motile spermatozoa in semen”. The target population 
proposed by the applicant is “men from the normal population with a wish to father a child”. 
Spermatozoa are constituents of normal semen and are needed for fertilisation of the female ova. The 
total number of spermatozoa per ejaculate as well as their properties, i.e. motility, viability and 
morphology, are key determinants of male fertility. Increasing the number of motile spermatozoa in 
semen may contribute to the fertility of men. The Panel considers that an increase in the number of 
motile spermatozoa in semen is a beneficial physiological effect. 
The applicant provided one unpublished intervention study which assessed the effects of the food that 
is the subject of the health claim on the number of motile spermatozoa in semen (i.e. the claimed 
effect) in vivo in humans. 
This double-blind, randomised, controlled, parallel trial was carried out in 70 Danish men who 
received pomegranate extract (1 000 mg per day) plus greater galangal powder (764 mg per day) or a 
placebo for three months. The primary outcome of the study was total motile sperm count (TMSC). 
Sperm morphology was assessed as a secondary outcome. For the statistical analysis, an unequal 
variance t-test was used. In a secondary analysis, adjustments were made in a linear regression model 
for age and body mass index (BMI), both dichotomised at the median. When the mean changes (i.e. 
end of the study versus baseline) in TMSC were compared, a statistically significant difference 
(+10.5 million; 95 % confidence interval (CI): 1.3–19.7, p = 0.026) was found between the 
pomegranate/greater galangal-group (+14.5 ± 21.3 million) and the control group (+4.0 ± 
15.2 million). When the analysis was adjusted for age and BMI, the difference between the groups 
remained significant (+9.8 million; 95 % CI: 0.2–19.5; p = 0.047). No differences were found for the 
secondary outcome between the groups. The Panel notes that this study shows an effect of the food on 
an increase in the number of motile spermatozoa in semen. 
With regards to the mechanism by which the food could exert the claimed effect, the applicant 
claimed that data from some human and animal studies suggest a complementary mode of action for 
each of the two major constituents of the food that is the subject of the claim: greater galangal would 
increase blood testosterone concentrations, whereas pomegranate would exert a “direct antioxidant 
effect” through ellagic acid and urolithins, and an “indirect antioxidant effect” by up-regulating serum 
paraoxonase, which would lead to lower oxidative stress and to the protection of sperm from 
oxidative damage. 
The applicant provided 18 human studies, 20 animal studies and two in vitro studies in support of a 
mechanism by which the two major constituents of the food could exert the claimed effect. 
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Two human studies and three animal studies were submitted only as abstracts, which did not allow a 
full scientific evaluation by the Panel. Therefore, no conclusions can be drawn from these studies on 
the mechanism by which the food could exert the claimed effect. 
The remaining 16 human studies were carried out with various preparations of pomegranate or 
isolated compounds thereof. The Panel notes that these studies did not assess whether or not the food 
could protect sperm from oxidative damage, or the extent to which the protection of sperm from 
oxidative damage could result in an increase in the number of motile spermatozoa in semen. 
The 17 animal studies were performed in a variety of species (i.e. mice, rats, rabbits and roosters) and 
models (e.g. animals with chemically induced testicular and/or spermatozoal toxicity). Two animal 
studies investigated the effects of greater galangal extracts. The Panel notes that these studies do not 
provide evidence that greater galangal extracts induce an increase in plasma testosterone 
concentrations which would affect the number of motile spermatozoa in semen. The remaining 
15 animal studies investigated the effects of various preparations of pomegranate. The Panel 
considers that these studies do not provide evidence for an effect of the pomegranate preparations 
used on the protection of sperm against oxidative damage or on the extent to which the protection of 
sperm against oxidative damage might increase the number of motile spermatozoa in semen. The 
Panel also notes that these studies do not provide evidence that changes in plasma testosterone 
concentrations would consistently affect the number of motile spermatozoa in semen. 
The two in vitro studies were performed in human immortalised cell lines and investigated the redox 
properties of various urolithins and urolithin derivatives. The Panel notes that the capacity of foods to 
scavenge free radicals in vitro does not provide information about their potential to decrease oxidative 
damage to molecules in vivo. 
The Panel considers that the human, animal and in vitro studies do not provide evidence for a 
mechanism by which a combination of pomegranate pomace extract and greater galangal rhizome 
powder could increase the number of motile spermatozoa in semen. 
In weighing the evidence, the Panel took into account that one human study showed an increase in the 
number of motile spermatozoa in semen when the combination of pomegranate pomace extract and 
greater galangal rhizome powder was consumed for three months, that no other human studies in 
which these results have been replicated were provided, and that no evidence was provided for a 
mechanism by which the food could exert the claimed effect. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the combination of pomegranate pomace extract (standardised by its content of 
punicalagins) and greater galangal rhizome powder (standardised by its content of acetoxychavicol 
acetate) and an increase in the number of motile spermatozoa in semen. 
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BACKGROUND 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of 
this Regulation, are authorised in accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this 
Regulation lays down provisions for the addition of claims (other than those referring to the reduction 
of disease risk and to children’s development and health) which are based on newly developed 
scientific evidence, or which include a request for the protection of proprietary data, to the 
Community list of permitted claims referred to in Article 13(3). 
According to Article 18 of this Regulation, an application for inclusion in the Community list of 
permitted claims referred to in Article 13(3) shall be submitted by the applicant to the national 
competent authority of a Member State, which will make the application and any supplementary 
information supplied by the applicant available to the European Food Safety Authority (EFSA). 
STEPS TAKEN BY EFSA 
 The application was received on 04/08/2014. 
 The scope of the application was proposed to fall under a health claim based on newly 
developed scientific evidence. The application included a request for the protection of 
proprietary data. 
 On 16/09/2014, during the validation process of the application, EFSA sent a request to the 
applicant to provide missing information. 
 On 22/09/2014, EFSA received the missing information as submitted by the applicant. 
 The scientific evaluation procedure started on 22/10/2014. 
 On 27/11/2014, the Working Group on Claims of the NDA Panel agreed on a list of questions 
for the applicant to provide additional information to accompany the application, and the 
scientific evaluation was suspended on 16/12/2014, in compliance with Article 18(3) of 
Regulation (EC) No 1924/2006. 
 On 26/12/2014, EFSA received the applicant’s reply and the scientific evaluation was 
restarted, in compliance with Article 18(3) of Regulation (EC) No 1924/2006. 
 During its meeting on 22/04/2015, the NDA Panel, having evaluated the data submitted, 
adopted an opinion on the scientific substantiation of a health claim related to a combination 
of pomegranate pomace extract and greater galangal rhizome powder and an increase in the 
number of motile spermatozoa in semen. 
TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with 
Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
opinion on the scientific substantiation of a health claim related to: a combination of pomegranate 
pomace extract and greater galangal rhizome powder and an increase in the number of motile 
spermatozoa in semen. 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
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EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation for the 
marketing of a combination of pomegranate pomace extract and greater galangal rhizome powder, a 
positive assessment of its safety, nor a decision on whether a combination of pomegranate pomace 
extract and greater galangal rhizome powder is, or is not, classified as a foodstuff. It should be noted 
that such an assessment is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006. 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address 
Nerthus ApS, Blaesenborgvej 9, DK-4320 Lejre, Denmark. 
The application includes a request for the protection of proprietary data for one unpublished study 
(Fedder et al.), in accordance with Article 21 of Regulation (EC) No 1924/2006. 
Food/constituent as stated by the applicant 
According to the applicant, the food that is the subject of the health claim is a combination of an 
extract of the fruit pomace of pomegranate (Punica granatum L.), standardised to the content of 
punicalagins (min. 30 %), and freeze-dried powder of the rhizome of greater galangal (Alpinia 
galanga (L.) Willd.), standardised to the content of 1´S-1´-acetoxychavicol acetate (min. 4 %). 
Health relationship as claimed by the applicant 
According to the applicant, daily consumption of a combination of pomegranate pomace extract and 
greater galangal rhizome powder increases the number of motile spermatozoa in semen. 
The applicant indicated that the exact mechanism by which the food might exert the claimed effect is 
not known. However, the applicant claims that some evidence suggests a testosterone-enhancing 
effect, primarily originating from greater galangal, and an antioxidant effect, primarily originating 
from pomegranate (comprising a “direct antioxidant effect”, caused by ellagic acid and urolithins, and 
an “indirect antioxidant effect”, caused by the up-regulation of serum paraoxonase). 
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wording for the health claim: “A combination of 
standardised pomegranate pomace extract and greater galangal rhizome powder increases the number 
of motile spermatozoa in semen”. 
Specific conditions of use as proposed by the applicant 
The applicant has proposed a daily intake of 1 000 mg pomegranate pomace extract (containing at 
least 300 mg of punicalagins and at least 400 mg of punicalagins, punicalins, ellagic acid glycosides 
and ellagic acid) and 764 mg of greater galangal rhizome powder (containing 16 mg acetoxychavicol 
acetate), which should be divided in two doses to be consumed in the morning and the evening. The 
target population proposed by the applicant is “men from the normal population with a wish to father 
a child”. 
ASSESSMENT 
1. Characterisation of the food/constituent 
The food that is the subject of the health claim is a combination of pomegranate pomace extract and 
greater galangal rhizome powder. 
The source of the pomegranate extract is the pomace, i.e. mashed fruit (a by-product of juice 
production) of pomegranate (Punica granatum L.), which is subjected to ethanol extraction, followed 
by concentration and spray drying. The extract is standardised by its content of punicalagins 
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(min. 30 %). The amount of total punicosides (i.e. punicalagins, punicalins, ellagic acid glycosides 
and ellagic acid) in the extract is at least 40 %. 
The source of greater galangal powder are the rhizomes of Alpinia galanga (L.) Willd., which are 
freeze-dried and powdered (milled). The powder is standardised by its content of 1´S-1´-
acetoxychavicol acetate (ACA; min. 4 %). 
The two ingredients, pomegranate extract and greater galangal powder, may be provided as separate 
formulations. 
An overview of the manufacturing process, batch-to-batch variability and stability data were provided 
for both ingredients. 
The Panel considers that the food, a combination of pomegranate pomace extract (standardised by its 
content of punicalagins) and greater galangal rhizome powder (standardised by its content of ACA), 
which is the subject of the health claim, is sufficiently characterised. 
2. Relevance of the claimed effect to human health 
The claimed effect is “increases the number of motile spermatozoa in semen”. The target population 
proposed by the applicant is “men from the normal population with a wish to father a child”. 
The applicant was requested to define the function of the body which is the target of the claim, and to 
provide evidence that an improvement in this function is a beneficial physiological effect for the 
target population of the claim. In reply, the applicant indicated that the targeted function of the body 
is “the production of motile spermatozoa in man, which is essential in relation to male fertility and 
reproductive health”. The applicant argued that “an improvement in the production of motile 
spermatozoa in a normal man would increase the chances of making a female partner pregnant”. The 
applicant provided three prospective observational studies (Beltsos et al., 1996; Larsen et al., 2000; 
Zinaman et al., 2000) in which the percentage of motile sperm and the total number of motile sperm 
were significantly associated with pregnancy rates. 
Spermatozoa are constituents of normal semen and are needed for fertilisation of the female ova. The 
total number of spermatozoa per ejaculate as well as their properties, i.e. motility, viability and 
morphology, are key determinants of male fertility. Reference values for sperm parameters have been 
established (Cooper et al., 2010; WHO, 2010). Increasing the number of motile spermatozoa in semen 
may contribute to the fertility of men. 
The Panel considers that an increase in the number of motile spermatozoa in semen is a beneficial 
physiological effect. 
3. Scientific substantiation of the claimed effect 
The applicant performed a literature search in Embase, MEDLINE, Web of Science Core Collection, 
BIOSIS Citation Index and BIOSIS Previews. For literature related to pomegranate fruit, the 
following search string was used: (“Punica” or “pomegranate” or “punical*” or “ellagitannin*” or 
“ellagic acid” or “urolithin*) and (“sperm” or “semen” or “testosterone”). In order to retrieve 
literature on greater galangal, the applicant used the following search string: (“Alpinia” or “galanga*” 
or “acetoxychavicol acetate” or “ACA”) and (“sperm” or “semen” or “testosterone”). Studies were 
included if they investigated any effect of 1) preparations of the rhizome of greater galangal or ACA; 
or 2) preparations of pomegranate fruit or ellagitannins of pomegranate fruit (including punicalagins 
or punicalins), or metabolites of ellagitannins (urolithins or ellagic acid), on sperm characteristics or 
testosterone levels. Studies not directly related to sperm quality or characteristics, or studies carried 
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out in diseased populations (e.g. diabetic patients) or populations outside the target population of the 
claim (e.g. the elderly), were excluded. 
Studies investigating the effect of the food on the number of motile spermatozoa in semen  
Human studies 
The applicant provided one unpublished intervention study (subsequently published as Fedder, 2014) 
which assessed the effects of the food that is the subject of the health claim on the number of motile 
spermatozoa in semen (i.e. the claimed effect) in vivo in humans. 
A double-blind, randomised, controlled, parallel trial (Fedder et al., unpublished study report, claimed 
as proprietary by the applicant; Fedder et al., 2014) was carried out in 70 Danish men (four 
participants chose to withdraw after enrolment, owing to “logistic difficulties”). The study subjects 
were randomised to receive pomegranate extract and greater galangal powder (n = 32, mean age 30.6 
± 7.3 years) or a placebo (microcrystalline cellulose; n = 34, mean age 28.1 ± 6.1 years) for three 
months. Four tablets of pomegranate extract plus four tablets of greater galangal powder were taken 
daily (two of each in the morning and in the evening), providing a daily dose of 1000 mg pomegranate 
extract and 764 mg of greater galangal powder. These amounts provided 106 mg punicalagin A, 
278 mg punicalagin B, 4.7 mg punicalin, 9.6 mg ellagic acid and 16 mg ACA. In order to be eligible 
for inclusion in the study, participants had to be healthy adult men of at least 18 years of age with a 
semen quality of less than 200 million motile sperm (total motile sperm count (TMSC)) per ejaculate. 
Men with azoospermia were excluded from the study. 
The primary outcome of the study was TMSC (determined by: ejaculate volume  spermatozoa 
concentration  percentage of motile spermatozoa). Assuming an expected TMSC difference of 
5 million between the study groups and a standard deviation (SD) of 2.3 million, it was estimated that 
18 participants per group were needed in order to achieve a statistical power of 80 % (at a 
significance level of 5 %). Owing to the high level of uncertainty of the assumptions in this power 
calculation, almost twice as many participants were enrolled. Sperm morphology was assessed as a 
secondary outcome. The study was approved by the Scientific Ethics Committee of Middle Jutland. 
The participants delivered two ejaculates at baseline (within a time span of 7–14 days and with  
3–7 days of abstinence from ejaculation before each sample delivery), one ejaculate after 4–8 days of 
tablet intake, and two more ejaculates (within a time span of 4–10 days and with 3–7 days of 
abstinence from ejaculation before each sample delivery) at the end of the study (i.e. after 
three months). The baseline TMSC values (average of the two ejaculates ± SD) were 23.4 ± 
25.1 million (95 % CI: 14.3–32.4) for the pomegranate/greater galangal-group and 19.9 ± 22.7 million 
(95 % CI: 12.0–27.8) for the placebo-group. 
For the statistical analysis, an unequal variance t-test (i.e. Welch’s t-test) was used, accounting for 
possible variance heterogeneity between the two groups. Data were inspected for normality using 
normal percentile plots (Q-Q plots). The applicant stated that there was a moderate departure from 
normality with a moderately right-skewed distribution. The applicant considered the t-test sufficiently 
robust to this moderate violation of the normality assumption. Moreover, as a confirmation analysis, 
all 95 % CIs and p-values were validated using the non-parametric bootstrap method. In a secondary 
analysis, adjustments were made in a linear regression model for age and body mass index (BMI), 
both dichotomised at the median. The average compliance (i.e. an intake of more than 80 % of the 
tablets) was 88 % in the pomegranate/greater galangal group and 91 % in the placebo group. 
When the mean changes (i.e. end of the study versus baseline) in TMSC were compared between the 
groups, a statistically significant difference (+10.5 million; 95 % CI: 1.3–19.7, p = 0.026) was found 
between the pomegranate/greater galangal group (+14.5 ± 21.3 million) and the control group (+4.0 ± 
15.2 million). When the analysis was adjusted for age and BMI, the difference between the groups 
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remained significant (+9.8 million; 95 % CI: 0.2–19.5; p = 0.047). No differences were found for the 
secondary outcome (i.e. sperm morphology) between the groups. 
The Panel notes that this study shows an increase in the number of motile spermatozoa in semen after 
daily consumption of 1000 mg pomegranate pomace extract and 764 mg greater galangal rhizome 
powder for three months. 
Animal studies 
A number of animal studies, which investigated the effect of an intervention on the number of motile 
spermatozoa in semen, were submitted by the applicant. The studies were carried out with various 
preparations of greater galangal or pomegranate, or isolated compounds thereof. The Panel notes that 
none of these studies was conducted with a food complying with the specifications of the food for 
which the claim was proposed (see section 1). Therefore, the Panel considers that none of these 
animal studies provides evidence for an effect of the food on the number of motile spermatozoa in 
semen, which could support the effect observed in the one human intervention study described above. 
Studies on the mechanisms by which the food could exert the claimed effect 
The applicant indicated that “the exact mechanism of the combination of pomegranate extract and 
galangal powder in relation to sperm quality is not known”. However, the applicant claims that data 
from some human and animal studies suggest a complementary mode of action for each of the two 
major constituents of the food that is the subject of the claim: greater galangal would increase blood 
testosterone concentrations, whereas pomegranate would exert a “direct antioxidant effect”, through 
ellagic acid and urolithins, and an “indirect antioxidant effect”, by up-regulating serum paraoxonase, 
which would lead to lower oxidative stress and to the protection of sperm from oxidative damage. 
The applicant provided 18 human studies, 20 animal studies and two in vitro studies in support of a 
mechanism by which the two major constituents of the food could exert the claimed effect. 
Two human studies (Al-Dujaili and Smail, 2012; Henning et al., 2013) and three animal studies 
(Amini Rad et al., 2009a, b; Bozkurt et al., 2014) were submitted as abstracts only, which did not 
allow a full scientific evaluation by the Panel. Therefore, no conclusions can be drawn from these 
studies on the mechanism by which the food could exert the claimed effect. 
Human studies 
The remaining 16 human studies (Aviram et al., 2000, 2004; Cerda et al., 2004; Seeram et al., 2004; 
Cerda et al., 2005; Mertens-Talcott et al., 2006; Seeram et al., 2006; Rock et al., 2008; Seeram et al., 
2008; Hajimahmoodi et al., 2009; González-Sarrías et al., 2010; Rosenblat et al., 2010; Balbir-
Gurman et al., 2011; Lynn et al., 2012; Parsaeyan et al., 2012; Basu et al., 2013) were concerned with 
the bioavailability of various pomegranate preparations and/or assessed outcomes on plasma total 
antioxidant status (e.g. by ferric reducing antioxidant potential and oxygen radical absorbance 
capacity assays), ex vivo low density lipoprotein (LDL) resistance to oxidation, serum oxidised-LDL 
(ox-LDL), serum anti-ox-LDL antibodies, serum malondialdehyde (MDA, determined by the 
thiobarbituric acid reactive substances (TBARS) assay) or serum paraoxonase activity after the 
consumption of various preparations of pomegranate or isolated compounds thereof. The Panel notes 
that none of these studies assessed whether or not the food could protect sperm from oxidative 
damage, or the extent to which the protection of sperm from oxidative damage could result in an 
increase in the number of motile spermatozoa in semen. 
Animal studies 
The 17 animal studies were performed in a variety of species (i.e. mice, rats, rabbits and roosters) and 
models (e.g. animals with chemically induced testicular and/or spermatozoal toxicity).  
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Two studies (Qureshi et al., 1992; Islam et al., 2000) investigated the effects of greater galangal 
extracts. Whereas one study (Islam et al., 2000) reported a significant increase in plasma testosterone 
concentrations after the consumption of a greater galangal extract compared with a placebo (number 
of motile spermatozoa was not assessed), the other study (Qureshi et al., 1992) reported a significant 
increase in the number of motile spermatozoa (testosterone concentrations were not assessed). The 
Panel notes that these studies do not provide evidence that greater galangal extracts induce an increase 
in plasma testosterone concentrations which would affect the number of motile spermatozoa in semen.  
The remaining 15 animal studies (Khalil, 2004; Türk et al., 2008a, b; Atessahin et al., 2010; Ceribasi 
et al., 2010; Türk et al., 2010a, b; Leiva et al., 2011; Sönmez et al., 2011; Abdou et al., 2012; Ceribasi 
et al., 2012; Dkhil et al., 2013; Mansour et al., 2013; Shanmugam and Rama Rao, 2013; Zeweil et al., 
2013) investigated the effects of various preparations of pomegranate (or isolated compounds thereof) 
on the activity of antioxidant enzymes (i.e. glutathione, glutathione peroxidase, superoxide dismutase, 
catalase) in plasma and/or testicular tissue, the concentration of MDA (determined by the TBARS 
assay) in plasma and/or testicular tissue, plasma testosterone concentrations, sperm motility, 
epididymal sperm concentrations and rates of abnormal sperm morphology. In a number of studies, an 
induction of the above-mentioned antioxidant enzymes and/or a decrease in the concentration of 
MDA (claimed to be a marker of lipid peroxidation) was observed after consumption of pomegranate 
preparations. The Panel notes that the induction of antioxidant enzymes is not a measure of protection 
against oxidative damage per se (EFSA NDA Panel, 2011), as the induction of such enzymes might 
reflect an increase in oxidative stress. The Panel notes that the studies did not investigate whether or 
not the induction of the antioxidant enzymes resulted in a protection of spermatozoa against oxidative 
damage. The Panel also notes that concentrations of MDA can only be used as supportive evidence 
for a protection against oxidative damage if appropriate techniques (e.g. high-performance liquid 
chromatography) are used for analysis (EFSA NDA Panel, 2011), which was not the case in the 
studies provided. Therefore, the Panel considers that these studies do not provide evidence for an 
effect of the pomegranate preparations used on the protection of sperm against oxidative damage or 
the extent to which the protection of sperm against oxidative damage might increase the number of 
motile spermatozoa in semen. 
The Panel notes that, although the applicant did not claim a testosterone-raising effect of 
pomegranate, eight animal studies assessed the effects of pomegranate preparations on plasma 
testosterone concentrations. Six of these studies also assessed sperm motility. The Panel considers 
that these six studies may provide information on how changes in plasma concentrations of 
testosterone in response to a dietary intervention may affect the number of motile spermatozoa in 
semen. The results from the studies are mixed. Whereas four studies found no increase in plasma 
testosterone concentration but an increase in sperm motility, one study reported an increase in plasma 
testosterone concentration but no increase in sperm motility, and one study did not show any effects 
on either plasma testosterone or sperm motility. The Panel notes that these animal studies do not 
provide evidence that changes in plasma testosterone concentrations would consistently affect the 
number of motile spermatozoa in semen. 
The two in vitro studies (Bialonska et al., 2009; Kallio et al., 2013) were performed in human 
immortalised cell lines and investigated the redox properties of various urolithins and urolithin 
derivatives. The Panel notes that the capacity of foods to scavenge free radicals in vitro does not 
provide information about their potential to decrease oxidative damage to molecules in vivo. 
The Panel considers that the human, animal and in vitro studies discussed in this section do not 
provide evidence for a mechanism by which a combination of pomegranate pomace extract and 
greater galangal rhizome powder could increase the number of motile spermatozoa in semen. 
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Weighing the evidence 
In weighing the evidence, the Panel took into account that one human study showed an increase in the 
number of motile spermatozoa in semen when the combination of pomegranate pomace extract and 
greater galangal rhizome powder was consumed for three months, that no other human studies in 
which these results have been replicated were provided, and that no evidence was provided for a 
mechanism by which the food could exert the claimed effect. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the combination of pomegranate pomace extract (standardised by its content of 
punicalagins) and greater galangal rhizome powder (standardised by its content of ACA) and an 
increase in the number of motile spermatozoa in semen. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 The food, a combination of pomegranate pomace extract (standardised by its content of 
punicalagins) and greater galangal rhizome powder (standardised by its content of ACA), 
which is the subject of the health claim, is sufficiently characterised. 
 The claimed effect proposed by the applicant is “increases the number of motile spermatozoa 
in semen”. The target population proposed by the applicant is “men from the normal 
population with a wish to father a child”. An increase in the number of motile spermatozoa in 
semen is a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of the 
combination of pomegranate pomace extract (standardised by its content of punicalagins) and 
greater galangal rhizome powder (standardised by its content of ACA) and an increase in the 
number of motile spermatozoa in semen. 
DOCUMENTATION PROVIDED TO EFSA 
1. Health claim application on a combination of pomegranate pomace extract and greater galangal 
rhizome powder and an increase in the number of motile spermatozoa in semen pursuant to 
Article 13(5) of Regulation (EC) No 1924/2006 (EFSA-Q-2014-00566; Claim serial 
No: 0424_DK). August 2014. Submitted by Nerthus ApS. 
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ABBREVIATIONS 
ACA  1´S-1´-acetoxychavicol acetate 
BMI  body mass index 
CI  confidence interval 
LDL  low-density lipoprotein 
MDA  malondialdehyde 
SD  standard deviation 
TBARS thiobarbituric acid reactive substances 
TMSC  total motile sperm count 
